Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Cardiology
•
Preventive Cardiology
Is there a role for routine stress testing in intermediate-high risk CAD patients with a significantly elevated coronary calcium score who are otherwise asymptomatic?
Related Questions
When would you consider initiating patients with CAD and aortic stenosis on PCSK9 inhibitors (as an adjunct to statin therapy), given favorable findings in the FOURIER trial?
What are some general thoughts you have on the clinical utility and value of high sensitivity troponin in patients when there is little clinical evidence for acute MI or acute decompensated heart failure, and lack of evidence to support non-ischemic myocardial injury?
What do you make of the results of the recent phase 2 RCT on Zerlasiran in terms of effectiveness at reducing lipoprotein (a) levels and the timing for when this will become readily available for patients who may benefit the most from it?
What is a reasonable way to treat statin-induced myalgia and what statin substitute would you consider using in the event the myalgia is not resolved?
Is there a role for colchicine in the management of patients after a myocardial infarction given the conflicting results of the COLCOT trial, which found a significant reduction in subsequent cardiovascular events, and the CLEAR SYNERGY (OASIS-9) trial, which did not find a significant benefit?
Have you begun to incorporate high dose IV iron infusions into your practice for patients newly started on hemodialysis with TSAT < 30% and ferritin < 400 to reduce risk for non-fatal CV events based on findings from the PIVOTAL trial?
What is your target or goal lipoprotein (a) level for patients on PCSK9 inhibitors for either primary or secondary prevention?
What are some potential etiologies to consider for isolated, mildly elevated BNP levels with normal TTE findings in an asymptomatic, elderly patient?
When would you consider long-term cardiac monitoring to look for atrial fibrillation in patients with mitral stenosis given their baseline elevated risk for atrial fibrillation and thrombosis?
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
